Antioxidative Theranostic Iron Oxide Nanoparticles toward Brain Tumors Imaging and ROS Production

• Published in: ACS chemical biology 2016-10, Vol.11 (10), p.2812-2819
• Main Authors: Richard, Sophie, Saric, Ana, Boucher, Marianne, Slomianny, Christian, Geffroy, Françoise, Mériaux, Sébastien, Lalatonne, Yoann, Petit, Patrice X, Motte, Laurence
• Format: Article
• Language: English
• Subjects: Antioxidants - pharmacology; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - metabolism; Cell Line, Tumor; Ferric Compounds - administration & dosage; Humans; Magnetic Resonance Imaging; Metal Nanoparticles; Microscopy, Electron, Transmission; Reactive Oxygen Species - metabolism; Theranostic Nanomedicine
• ISSN: 1554-8929; 1554-8937
• DOI: 10.1021/acschembio.6b00558

Gliomas are the most common primary brain tumor in humans. To date, the only treatment of care consists of surgical removal of the tumor bulk, irradiation, and chemotherapy, finally resulting in a very poor prognosis due to the lack of efficiency in diagnostics. In this context, nanomedicine combining both diagnostic and magnetic resonance imaging (MRI) and therapeutic applications is a relevant strategy referred to theranostic. Magnetic nanoparticles (NP) are excellent MRI contrast agents because of their large magnetic moment, which induces high transverse relaxivity (r 2) characteristic and increased susceptibility effect (T2*). NP can be also used for drug delivery by coating their surface with therapeutic molecules. Preliminary in vitro studies show the high potential of caffeic acid (CA), a natural polyphenol, as a promising anticancer drug due to its antioxidant, anti-inflammatory, and antimetastatic properties. In this study, the antioxidative properties of iron oxide NP functionalized with caffeic acid (γFe2O3@CA NP) are investigated in vitro on U87-MG brain cancer cell lines. After intravenous injection of these NP in mice bearing a U87 glioblastoma, a negative contrast enhancement was specifically observed on 11.7 T MRI images in cancerous tissue, demonstrating a passive targeting of the tumor with these nanoplatforms.